Latest Headlines

Latest Headlines

Detoxified anthrax used to deliver cancer drugs within cells

MIT scientists have employed a harmless version of the anthrax causing bacteria for drug delivery purposes, using it to insert drugs known as antibody mimics inside cells in the fight against cancer. 

CDC takes steps to improve lab safety after anthrax, flu scares

In response to back-to-back incidents involving government laboratories, a top official at the U.S. Centers for Disease Control and Prevention has resigned, and the agency has assembled a safety board to address concerns that have arisen after workers were potentially exposed to anthrax and H5N1 flu.

Vaccine prevents anthrax infection in preclinical tests

Biodefense company Soligenix revealed new data showing that a combination of its vaccines RiVax and VeloThrax induced protective immunity to both ricin toxin and anthrax toxin exposure in an animal study.

PharmAthene anthrax vax aces survival in rabbit study

PharmAthene's anthrax vaccine candidate, SparVax, works at least as well as currently licensed BioThrax from Emergent BioSolutions--at least, according to a study in New Zealand white rabbits.

Blessed by Gates, crowdfunding site funnels cash for high-risk R&D

A new crowdfunding platform site called Microryza has started funneling cash to dozens of high-risk scientific research programs, including a number of drug development efforts that would otherwise never see the light of day.

FDA green-lights new anti-anthrax, rare disease drugs from GlaxoSmithKline and Novartis

The FDA is wrapping up business before the end of the year and making a flurry of approvals. The agency OK'd three new drugs Friday, with all of the green-lighted therapies sanctioned for combating relatively rare ailments and securing orphan drug status.

FhCMB nabs up to $9.9M from NIH for anthrax vaccine research

Fraunhofer Center for Molecular Biotechnology could receive up to $9.9 million in funding from NIH's National Institute of Allergy and Infectious Diseases to develop the next generation of anthrax vaccines.

U.K.'s HPA lands $6.4M for anthrax vaccine research

The U.S. government doled out a contract worth £4 million ($6.4 million) to the U.K.'s Health Protection Agency to develop a next-generation anthrax vaccine. The project will be valued at £14 million ($22.6 million) if all milestones are met.

Cardiff University works on anthrax vaccine for NATO

Scientists from the U.K.'s Cardiff University are leading a NATO project to develop an anthrax vaccine.

NJ biotech wins $14.5M from U.S. gov't to study drug against anthrax

Uncle Sam has ponied up another $14.5 million in funding to advance Elusys Therapeutics' experimental drug for treating patients after anthrax attacks, according to the company. And the Pine Brook, NJ-based biopharma group is working on a plan for late-stage development of the antibody drug, ETI-204 or Anthim.
  • 1
  • 2
  • 3
  • next ›
  • last »